Possible coronavirus treatment found as cheap steroid impresses in Oxford University trial

According to research at Oxford University, it reduces death by up to one third in patients with severe symptoms


The University of Oxford has announced that a low dose of steroid treatment dexamethasone reduces death by up to one third in patients with severe COVID-19 symptoms.

The drug, which is cheap and widely available, was studied as part of the RECOVERY trial established in March, involving 11,500 patients across 175 hospitals in the UK.

READ: Coronavirus: What’s happening in the labs of pharma companies worldwide

According to the research, one death would be prevented by treatment of around eight ventilated patients or around 25 patients requiring oxygen alone.

“This is tremendous news today from the Recovery trial showing that dexamethasone is the first drug to reduce mortality from COVID-19,” said the UK Government’s chief scientific adviser, Sir Patrick Vallance.

“It is particularly exciting as this is an inexpensive widely available medicine.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Analyst Davide Bosio on uranium euphoria and why gold equities are still cheap

Davide Bosio from Australia's Shaw and Partners tells Proactive the recent strength in the uranium market has been 'phenomenal' and we've seen the likes of Sprott purchasing significant amounts of physical uranium and they've indicated they're upscaling that by another US$1 billion which he says...

18 minutes ago

2 min read